Sex differences in response to tadalafil in pulmonary arterial hypertension

DOI: 10.1378/chest.14-0263
Chest, 2015, 147, 188-197.

#	Paper	IF	Citations
52	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. *Core Evidence*, **2015**, 10, 99-109	4.9	19
51	Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2015**, 308, L873-90	5.8	83
50	Sex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening. *Pulmonary Circulation*, **2015**, 5, 701-6	2.7	6
49	Pulmonary Arterial Hypertension and the Sex Hormone Paradox. *Current Hypertension Reports*, **2016**, 18, 84	4.7	32
48	Gender-related differences in pulmonary arterial hypertension targeted drugs administration. *Pharmacological Research*, **2016**, 114, 103-109	10.2	25
47	17β-Estradiol mediates superior adaptation of right ventricular function to acute strenuous exercise in female rats with severe pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2016**, 311, L375-88	5.8	46
46	Effect of Age on Phenotype and Outcomes in Pulmonary Arterial Hypertension Trials. *Chest*, **2016**, 149, 1234-44	5.3	9
45	The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. *Annals of the American Thoracic Society*, **2016**, 13, 842-9	4.7	22
44	Effects of in utero and Postnatal Exposure to Secondhand Smoke on Lung Function by Gender and Asthma Status: The Seven Northeastern Cities (SNEC) Study. *Respiration*, **2017**, 93, 189-197	3.7	25
43	Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. *Current Medical Research and Opinion*, **2017**, 33, 963-971	2.5	2
42	Sex-specific cardiopulmonary exercise testing indices related to hemodynamics in idiopathic pulmonary arterial hypertension. *Therapeutic Advances in Respiratory Disease*, **2017**, 11, 135-145	4.9	6
41	Identifying "super responders" in pulmonary arterial hypertension. *Pulmonary Circulation*, **2017**, 7, 300-311	2.7	7
40	Novel approach to classifying patients with pulmonary arterial hypertension using cluster analysis. *Pulmonary Circulation*, **2017**, 7, 486-493	2.7	9
39	Sex differences in pulmonary vascular control: focus on the nitric oxide pathway. *Physiological Reports*, **2017**, 5, e13200	2.6	3
38	Sex differences in hemodynamic responses and long-term survival to optimal medical therapy in patients with pulmonary arterial hypertension. *Heart and Vessels*, **2018**, 33, 939-947	2.1	7
37	Pulmonary arterial hypertension: pathogenesis and clinical management. *BMJ, The*, **2018**, 360, j5492	5.9	312
36	Sex-specific echocardiographic reference values: the women's point of view. *Journal of Cardiovascular Medicine*, **2018**, 19, 527-535	1.9	10

35	Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 1090-1093	10.2	2
34	Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 51,	13.6	4
33	Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 51,	13.6	33
32	The Role of Sex in the Pathophysiology of Pulmonary Hypertension. *Advances in Experimental Medicine and Biology*, **2018**, 1065, 511-528	3.6	22
31	Nothing but a Number? Age and Precision Treatment in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 986-988	10.2	
30	Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 850-858	10.2	44
29	Sex-Specific Contributions of Endothelin to Hypertension. *Current Hypertension Reports*, **2018**, 20, 58	4.7	16
28	Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008-2016. *ERJ Open Research*, **2019**, 5,	3.5	8
27	Personalisierte Medizin bei pulmonaler Hypertonie. *Pneumologe*, **2019**, 16, 76-87	0.1	
26	Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. *Comprehensive Physiology*, **2019**, 10, 125-170	7.7	39
25	Relative Importance of Baseline and Longitudinal Evaluation in the Follow-Up of Vasodilator Therapy in Pulmonary Arterial Hypertension. *JACC: Cardiovascular Imaging*, **2019**, 12, 2103-2111	8.4	11
24	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 151-161	15.4	22
23	Sex Differences in Portopulmonary Hypertension. *Chest*, **2021**, 159, 328-336	5.3	2
22	Cardiovascular Medications. **2021**, 597-642		1
21	Sex Differences in Pulmonary Arterial Hypertension. *Physiology in Health and Disease*, **2021**, 197-249	0.2	1
20	Experimental design of the Effects of Dehydroepiandrosterone in Pulmonary Hypertension (EDIPHY) trial. *Pulmonary Circulation*, **2021**, 11, 2045894021989554	2.7	0
19	Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension. *Pulmonary Circulation*, **2021**, 11, 20458940211025240	2.7	3
18	Newer insights into the pathobiological and pharmacological basis of the sex disparity in patients with pulmonary arterial hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2021**, 320, L1025-L1037	5.8	1

17	Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop. *Circulation: Heart Failure*, **2021**, 14,	7.6	1
16	Advances in the management of pulmonary arterial hypertension. *Journal of Investigative Medicine*, **2021**, 69, 1270-1280	2.9	4
15	Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes. *Current Opinion in Pharmacology*, **2021**, 60, 298-305	5.1	1
14	Biomarkers in Pulmonary Hypertension. **2022**, 597-604		
13	Sex-based differences in veterans with pulmonary hypertension: Results from the veterans affairs-clinical assessment reporting and tracking database. *PLoS ONE*, **2017**, 12, e0187734	3.7	13
12	Pulmonary Arterial Hypertension in Women. *Methodist DeBakey Cardiovascular Journal*, **2017**, 13, 224-237	1.1	8
11	Current and Emerging Biomarkers for Pulmonary Hypertension. *Advances in Pulmonary Hypertension*, **2018**, 16, 136-140	0.5	1
10	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. *Current Medicinal Chemistry*, **2020**, 27, 7168-7188	4.3	10
9	Sex Differences in Pulmonary Hypertension. *Frontiers in Aging*, **2021**, 2,	2.5	0
8	Sex-Specific Effects of Daily Tadalafil on Contraction Kinetics of the Diabetic Heart. The RECOGITO Randomized, Double-Blind, Placebo-Controlled Trial. *SSRN Electronic Journal*,	1	
7	Sex and gender in pulmonary arterial hypertension. *European Respiratory Review*, **2021**, 30,	9.8	2
6	Pulmonalarterielle Hypertonie bei Frauen. *Aktuelle Kardiologie*, **2022**, 11, 30-34	0.1	
5	Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. *Science Translational Medicine*, **2022**, 14,	17.5	1
4	Baseline Sex Differences in Pulmonary Arterial Hypertension Randomized Clinical Trials.		0
3	Sex and Gender in lung diseases and sleep disorders: A state of the art review. Part 2. **2022**,		0
2	A century of exercise physiology: lung fluid balance during and following exercise.		0
1	Sex- and Gender-Related Aspects in Pulmonary Hypertension. **2023**, 19, 11-24		0